• Anand Tandra, Fahrettin Covut, Brenda Cooper, Richard Creger, Lauren Brister, Bernadette McQuigg, Paolo Caimi, Ehsan Malek, Ben Tomlinson, Hillard M Lazarus, Folashade Otegbeye, Merle Kolk, Marcos de Lima, and Leland Metheny.
• a Stem Cell Transplant Program , University Hospitals Cleveland Medical Center and Case Western Reserve University , Cleveland , OH , USA.
• Leuk. Lymphoma. 2018 Jul 1; 59 (7): 1644-1651.

AbstractAnti-thymocyte globulin (ATG) is often added to hematopoietic stem cell transplant conditioning regimens to prevent graft rejection and reduce graft-versus-host disease (GVHD). Doses used in retrospective and prospective clinical trials have ranged from 2.5 to 20 mg/kg with rates of grade II-IV acute GVHD and chronic GVHD up to 40 and 60%, respectively. We retrospectively compared outcomes in recipients of matched unrelated donor (MUD) grafts given low dose rabbit ATG IV 3 mg/kg (n = 52) versus recipients of matched related donor (MRD) grafts (n = 48) without ATG. One year cumulative incidence of chronic GVHD was 25.2% in the MUD group versus 33.3% in the MRD group (p = .5). One-year cumulative incidence of extensive chronic GVHD was 9.6% in the MUD group versus 26.6% in the MRD group (p = .042). Our analysis supports the use of low dose ATG in MUD transplantation as an effective therapy to prevent chronic GVHD.

31 keywords...

hide…